Ritu Baral
Stock Analyst at TD Cowen
(2.96)
# 1,271
Out of 5,154 analysts
45
Total ratings
40%
Success rate
2.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ritu Baral
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $35 → $37 | $22.16 | +66.97% | 3 | Feb 26, 2026 | |
| KRYS Krystal Biotech | Maintains: Buy | $202 → $306 | $253.69 | +20.62% | 1 | Jan 9, 2026 | |
| VTVT vTv Therapeutics | Initiates: Buy | $67 | $35.22 | +90.23% | 1 | Jan 5, 2026 | |
| INSM Insmed | Maintains: Buy | $269 → $241 | $140.13 | +71.98% | 7 | Dec 18, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $97 → $133 | $134.39 | -1.03% | 3 | Dec 16, 2025 | |
| MIST Milestone Pharmaceuticals | Upgrades: Buy | $8 | $1.58 | +406.33% | 1 | Dec 15, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $251 → $353 | $310.71 | +13.61% | 1 | Dec 8, 2025 | |
| VERA Vera Therapeutics | Maintains: Buy | $60 → $73 | $39.07 | +86.84% | 2 | Dec 5, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $390 → $554 | $432.83 | +27.99% | 2 | Aug 26, 2025 | |
| SPRO Spero Therapeutics | Downgrades: Hold | n/a | $2.30 | - | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.85 | - | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $282 → $371 | $320.66 | +15.70% | 4 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.41 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $175 | $16.71 | +947.28% | 1 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $55.87 | - | 2 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.91 | - | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $15.93 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.39 | - | 2 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $42.82 | - | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.33 | - | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.32 | - | 2 | Jul 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $574.01 | - | 2 | Jan 12, 2018 |
ACADIA Pharmaceuticals
Feb 26, 2026
Maintains: Buy
Price Target: $35 → $37
Current: $22.16
Upside: +66.97%
Krystal Biotech
Jan 9, 2026
Maintains: Buy
Price Target: $202 → $306
Current: $253.69
Upside: +20.62%
vTv Therapeutics
Jan 5, 2026
Initiates: Buy
Price Target: $67
Current: $35.22
Upside: +90.23%
Insmed
Dec 18, 2025
Maintains: Buy
Price Target: $269 → $241
Current: $140.13
Upside: +71.98%
Palvella Therapeutics
Dec 16, 2025
Maintains: Buy
Price Target: $97 → $133
Current: $134.39
Upside: -1.03%
Milestone Pharmaceuticals
Dec 15, 2025
Upgrades: Buy
Price Target: $8
Current: $1.58
Upside: +406.33%
Praxis Precision Medicines
Dec 8, 2025
Maintains: Buy
Price Target: $251 → $353
Current: $310.71
Upside: +13.61%
Vera Therapeutics
Dec 5, 2025
Maintains: Buy
Price Target: $60 → $73
Current: $39.07
Upside: +86.84%
Madrigal Pharmaceuticals
Aug 26, 2025
Maintains: Buy
Price Target: $390 → $554
Current: $432.83
Upside: +27.99%
Spero Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.30
Upside: -
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.85
Upside: -
Oct 21, 2024
Maintains: Buy
Price Target: $282 → $371
Current: $320.66
Upside: +15.70%
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $5.41
Upside: -
Mar 22, 2023
Maintains: Outperform
Price Target: $125 → $175
Current: $16.71
Upside: +947.28%
Nov 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $55.87
Upside: -
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.91
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $15.93
Upside: -
Jul 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.39
Upside: -
Mar 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $42.82
Upside: -
Jun 29, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.33
Upside: -
Jul 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $0.32
Upside: -
Jan 12, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $574.01
Upside: -